233 related articles for article (PubMed ID: 32087735)
1. Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer.
Zhou Q; Perakis SO; Ulz P; Mohan S; Riedl JM; Talakic E; Lax S; Tötsch M; Hoefler G; Bauernhofer T; Pichler M; Gerger A; Geigl JB; Heitzer E; Speicher MR
Genome Med; 2020 Feb; 12(1):20. PubMed ID: 32087735
[TBL] [Abstract][Full Text] [Related]
2. FOXF1 promotes angiogenesis and accelerates bevacizumab resistance in colorectal cancer by transcriptionally activating VEGFA.
Wang S; Xiao Z; Hong Z; Jiao H; Zhu S; Zhao Y; Bi J; Qiu J; Zhang D; Yan J; Zhang L; Huang C; Li T; Liang L; Liao W; Ye Y; Ding Y
Cancer Lett; 2018 Dec; 439():78-90. PubMed ID: 30253191
[TBL] [Abstract][Full Text] [Related]
3. Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A.
Burgermeister E; Battaglin F; Eladly F; Wu W; Herweck F; Schulte N; Betge J; Härtel N; Kather JN; Weis CA; Gaiser T; Marx A; Weiss C; Hofheinz R; Miller IS; Loupakis F; Lenz HJ; Byrne AT; Ebert MP
EBioMedicine; 2019 Jul; 45():139-154. PubMed ID: 31300350
[TBL] [Abstract][Full Text] [Related]
4.
Papachristos A; Kemos P; Katsila T; Panoilia E; Patrinos GP; Kalofonos H; Sivolapenko GB
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31752122
[TBL] [Abstract][Full Text] [Related]
5. Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer.
Zuurbier L; Rahman A; Cordes M; Scheick J; Wong TJ; Rustenburg F; Joseph JC; Dynoodt P; Casey R; Drillenburg P; Gerhards M; Barat A; Klinger R; Fender B; O'Connor DP; Betge J; Ebert MP; Gaiser T; Prehn JHM; Griffioen AW; van Grieken NCT; Ylstra B; Byrne AT; van der Flier LG; Gallagher WM; Postel R
Oncotarget; 2017 Jun; 8(26):42949-42961. PubMed ID: 28487489
[TBL] [Abstract][Full Text] [Related]
6. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
Tsai HL; Lin CH; Huang CW; Yang IP; Yeh YS; Hsu WH; Wu JY; Kuo CH; Tseng FY; Wang JY
Int J Clin Exp Pathol; 2015; 8(2):1900-10. PubMed ID: 25973082
[TBL] [Abstract][Full Text] [Related]
7. Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab.
Pentheroudakis G; Mavroeidis L; Papadopoulou K; Koliou GA; Bamia C; Chatzopoulos K; Samantas E; Mauri D; Efstratiou I; Pectasides D; Makatsoris T; Bafaloukos D; Papakostas P; Papatsibas G; Bombolaki I; Chrisafi S; Kourea HP; Petraki K; Kafiri G; Fountzilas G; Kotoula V
Clin Colorectal Cancer; 2019 Dec; 18(4):e370-e384. PubMed ID: 31402291
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy.
Matsusaka S; Hanna DL; Cao S; Zhang W; Yang D; Ning Y; Sunakawa Y; Okazaki S; Berger MD; Miyamato Y; Parekh A; Stintzing S; Loupakis F; Lenz HJ
Clin Cancer Res; 2016 Jul; 22(13):3218-26. PubMed ID: 26839145
[TBL] [Abstract][Full Text] [Related]
9. Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5
Feng H; Liu K; Shen X; Liang J; Wang C; Qiu W; Cheng X; Zhao R
Cell Death Dis; 2020 Oct; 11(10):916. PubMed ID: 33099574
[TBL] [Abstract][Full Text] [Related]
10. Prediction of novel target genes and pathways involved in bevacizumab-resistant colorectal cancer.
Makondi PT; Lee CH; Huang CY; Chu CM; Chang YJ; Wei PL
PLoS One; 2018; 13(1):e0189582. PubMed ID: 29342159
[TBL] [Abstract][Full Text] [Related]
11. aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.
Fujita Y; Taguri M; Yamazaki K; Tsurutani J; Sakai K; Tsushima T; Nagase M; Tamagawa H; Ueda S; Tamura T; Tsuji Y; Murata K; Taira K; Denda T; Moriwaki T; Funai S; Nakajima TE; Muro K; Tsuji A; Yoshida M; Suyama K; Kurimoto T; Sugimoto N; Baba E; Seki N; Sato M; Shimura T; Boku N; Hyodo I; Yamanaka T; Nishio K
Oncologist; 2019 Mar; 24(3):327-337. PubMed ID: 30425180
[TBL] [Abstract][Full Text] [Related]
12. Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer.
Schiffmann LM; Fritsch M; Gebauer F; Günther SD; Stair NR; Seeger JM; Thangarajah F; Dieplinger G; Bludau M; Alakus H; Göbel H; Quaas A; Zander T; Hilberg F; Bruns CJ; Kashkar H; Coutelle O
Br J Cancer; 2019 Jan; 120(1):69-78. PubMed ID: 30377339
[TBL] [Abstract][Full Text] [Related]
13. A Qualitative Transcriptional Signature for Predicting Prognosis and Response to Bevacizumab in Metastatic Colorectal Cancer.
Yang J; Song K; Guo W; Zheng H; Fu Y; You T; Wang K; Qi L; Zhao W; Guo Z
Mol Cancer Ther; 2020 Jul; 19(7):1497-1505. PubMed ID: 32371582
[TBL] [Abstract][Full Text] [Related]
14. Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab.
van Dijk E; Biesma HD; Cordes M; Smeets D; Neerincx M; Das S; Eijk PP; Murphy V; Barat A; Bacon O; Prehn JHM; Betge J; Gaiser T; Fender B; Meijer GA; McNamara DA; Klinger R; Koopman M; Ebert MPA; Kay EW; Hennessey BT; Verheul HMW; Gallagher WM; O'Connor DP; Punt CJA; Loupakis F; Lambrechts D; Byrne AT; van Grieken NCT; Ylstra B
J Clin Oncol; 2018 Jul; 36(20):2052-2060. PubMed ID: 29792754
[TBL] [Abstract][Full Text] [Related]
15. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.
Iwai T; Sugimoto M; Harada S; Yorozu K; Kurasawa M; Yamamoto K
Oncol Rep; 2016 Aug; 36(2):626-32. PubMed ID: 27350037
[TBL] [Abstract][Full Text] [Related]
16. Changes in expression levels of ERCC1, DPYD, and VEGFA mRNA after first-line chemotherapy of metastatic colorectal cancer: results of a multicenter study.
Baba H; Baba Y; Uemoto S; Yoshida K; Saiura A; Watanabe M; Maehara Y; Oki E; Ikeda Y; Matsuda H; Yamamoto M; Shimada M; Taketomi A; Unno M; Sugihara K; Ogata Y; Eguchi S; Kitano S; Shirouzu K; Saiki Y; Takamori H; Mori M; Hirata T; Wakabayashi G; Kokudo N
Oncotarget; 2015 Oct; 6(32):34004-13. PubMed ID: 26372896
[TBL] [Abstract][Full Text] [Related]
17. Copy number and transcriptome alterations associated with metastatic lesion response to treatment in colorectal cancer.
Gambaro K; Marques M; McNamara S; Couetoux du Tertre M; Diaz Z; Hoffert C; Srivastava A; Hébert S; Samson B; Lespérance B; Ko YJ; Dalfen R; St-Hilaire E; Sideris L; Couture F; Burkes R; Harb M; Camlioglu E; Gologan A; Pelsser V; Constantin A; Greenwood CMT; Tejpar S; Kavan P; Kleinman CL; Batist G
Clin Transl Med; 2021 Apr; 11(4):e401. PubMed ID: 33931971
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics in Model-Based Optimization of Bevacizumab Therapy for Metastatic Colorectal Cancer.
Papachristos A; Karatza E; Kalofonos H; Sivolapenko G
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32466535
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
[TBL] [Abstract][Full Text] [Related]
20. Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer.
Wong HL; Lee B; Field K; Lomax A; Tacey M; Shapiro J; McKendrick J; Zimet A; Yip D; Nott L; Jennens R; Richardson G; Tie J; Kosmider S; Parente P; Lim L; Cooray P; Tran B; Desai J; Wong R; Gibbs P
Clin Colorectal Cancer; 2016 Jun; 15(2):e9-e15. PubMed ID: 26968236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
